Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Nupur Greene"'
1
Akademický článek
Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis
Autor: Nupur Greene, Stéphane Quéré, Denise P. Bury, Flora Mazerolle, Manal M’Hari, Angély Loubert, Antoine Regnault, Keiko Higuchi
Publikováno v: Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-14 (2023)
Abstract Background As disease-modifying therapies do not reverse the course of multiple sclerosis (MS), assessment of therapeutic success involves documenting patient-reported outcomes (PROs) concerning health-related quality of life, disease and tr
Externí odkaz: https://doaj.org/article/94182c688a5c44198acf541402a0d875
Zobrazit plný text záznamu
2
Akademický článek
Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
Autor: Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi, Nupur Greene
Publikováno v: Journal of Comparative Effectiveness Research, Vol 12, Iss 1 (2022)
Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). Patients & methods: Retrospectiv
Externí odkaz: https://doaj.org/article/a9395ad0d04741748bedca1d6f06478a
Zobrazit plný text záznamu
3
Akademický článek
The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis
Autor: Nupur Greene, Lita Araujo, Cynthia Campos, Hannah Dalglish, Sarah Gibbs, Irina Yermilov
Publikováno v: Journal of Health Economics and Outcomes Research, Vol 9, Iss 2 (2022)
**Background:** Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Pediatric-onset MS (POMS), defined as onset of MS before 18 years of age, is estimated to account for 2% to 5% of the MS population wo
Externí odkaz: https://doaj.org/article/b4c03337508a45eb99ff5ec3d6a17c8c
Zobrazit plný text záznamu
4
Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
Autor: Nupur Greene, Keiko Higuchi, Katalin Bognar, Eunice Chang, Michael S Broder
Publikováno v: ClinicoEconomics and Outcomes Research. 14:755-761
Nupur Greene,1 Keiko Higuchi,1 Katalin Bognar,2 Eunice Chang,2 Michael S Broder2 1Neurology & Immunology (N&I), Sanofi, Cambridge, MA, USA; 2Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USACorrespondence: N
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a77a13b3d5ce8b3a76cea8531caeb8
https://doi.org/10.2147/ceor.s383934
Zobrazit plný text záznamu
5
Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
Autor: Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi, Nupur Greene
Publikováno v: ClinicoEconomics and Outcomes Research.
Lita Araujo,1 Srikanth Kyatham,2 Kristen G Bzdek,1 Keiko Higuchi,1 Nupur Greene1 1Neurology and Immunology, Sanofi, Cambridge, MA, USA; 2Axtria Inc, Berkeley Heights, NJ, USACorrespondence: Lita Araujo, Neurology and Immunology, Sanofi, 450 Water Str
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81829cb274f4b27a5f3b3dc5a0fdafbe
https://www.dovepress.com/assessing-the-health-economic-outcomes-from-commercially-insured-relap-peer-reviewed-fulltext-article-CEOR
Zobrazit plný text záznamu
7
Influence of Comorbidities on Healthcare Expenditures and Perceived Physical and Mental Health Status Among Adults with Multiple Sclerosis: A Propensity Score-Matched US National-Level Study
Autor: Kevin Duhrkopf, Nupur Greene, Sandipan Bhattacharjee, Kristin Kollecas, Lobat Hashemi, Zufan Yegezu
Publikováno v: ClinicoEconomics and Outcomes Research: CEOR
Sandipan Bhattacharjee,1 Zufan Yegezu,2 Kristin Kollecas,3 Kevin Duhrkopf,3 Lobat Hashemi,3 Nupur Greene3 1Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA; 2Department of Pharmacy Practice and Science
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25db217c69152794bc66a3908637ab9e
https://doi.org/10.2147/ceor.s305154
Zobrazit plný text záznamu
8
Work productivity loss among adults aged 18-64 years with Multiple Sclerosis in the United States: A propensity score matched study
Autor: Sandipan Bhattacharjee, Zufan Yegezu, Kristin Kollecas, Kevin Duhrkopf, Nupur Greene, Lobat Hashemi
Publikováno v: Research in socialadministrative pharmacy : RSAP. 18(11)
Scarce data exists regarding United States (US) national-level work productivity loss among adults with Multiple Sclerosis (MS).To address this significant knowledge gap, we examined the national-level productivity loss among adults (18≤ age ≤64
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8950d889f9b8928b36c645a8f0d0ac8e
https://pubmed.ncbi.nlm.nih.gov/35934667
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje